Remote stroke diagnosis and treatment platform (RESDAT)

Lead Participant: BRAINOMIX LIMITED

Abstract

Rapid diagnosis and treatment of stroke is critical in improving outcomes for stroke, which is the leading cause of serious long-term disability globally. Stroke is the fourth largest cause of death in the UK and costs £25.6 billion annually.

The most common type of stroke is a large vessel occlusion which is a clot lodged in a major artery in the brain. Multiple clinical studies to have shown that patients have the best outcomes when treated with mechanical thrombectomy. Thrombectomy is a medical procedure where a specialist physician removes a blood clot from a blocked artery by making a small incision in the groin or arm, and using a catheter (thin, flexible tube) to guide a device through blood vessels in the body to the clot in the brain for removal.

However, there are still many risks involved in mechanical thrombectomy for the patient and the clinicians. For the patient, there are risks of injury to the blood vessels. To address these problems, we want to create a robotic system that can improve the accuracy, availability, and safety of thrombectomy. The system will provide the following benefits:

\***More accurate clot removal:** Robots can be programmed to move with more precision than human hands, which can help to ensure that the clot is removed completely and can help to reduce the risk of damage that is caused during the procedure.

\***Widen access to underserved populations:** Thrombectomies will not require the physical presence of a highly trained operator meaning that it will be easier and more cost-effective to enable access in remote areas at any time.

\***Less exposure to radiation:** Clinicians are exposed to higher than normal levels of radiation to carry out these procedures that need to be carried out regularly to save lives.

Through this project, Brainomix, the leading stroke AI company in the UK & Europe, and Nanoflex, a robotics spin-off from ETH Zurich, will partner to develop a novel platform to be able to delicately guide more effective devices through to clots.

Lead Participant

Project Cost

Grant Offer

BRAINOMIX LIMITED £569,638 £ 398,747
 

Participant

INNOVATE UK

Publications

10 25 50